Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Target validation of ACLY as a novel anti-cancer drug target for hepatocellular carcinoma
FY 2018-19
Summary
ATP citrate lyase (ACLY) performs an essential role in de novo lipogenesis by catalyzing the synthesis of cytosolic acetyl-CoA. De novo lipogenesis is upregulated in cancer in order to compensate for the metabolic demands of rapid cell proliferation. This is because lipid is an important macromolecule for cell proliferation due to its roles in membrane biogenesis, cell signaling and energy production/storage. Therefore, it is not surprising that ACLY is upregulated in various types of cancer and correlates with poor patient prognosis. However, the role of ACLY in hepatocellular carcinoma (HCC) remains largely unknown. Currently, the net 5 year survival rate of HCC is 19% and its incidence is rapidly increasing in Canada. Unfortunately, Sorafenib and Lenvatinib, the lone first-line standard of treatment drugs for HCC, could only extend median survival by 3 - 4 months. Thus, validation of ACLY as a novel drug target for HCC either alone or in combination with these drugs is of critical interest for improving the standard of care for HCC. The proposed study aims to discover and validate the role of ACLY in HCC through both pharmacological and genetic inhibition of ACLY activity.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406582
Name
Wu Jianhan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Target validation of ACLY as a novel anti-cancer drug target for hepatocellular carcinoma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
De Novo Lipogenesis; Hepatocellular Carcinoma; Liver Disease
Abstract
ATP citrate lyase (ACLY) performs an essential role in de novo lipogenesis by catalyzing the synthesis of cytosolic acetyl-CoA. De novo lipogenesis is upregulated in cancer in order to compensate for the metabolic demands of rapid cell proliferation. This is because lipid is an important macromolecule for cell proliferation due to its roles in membrane biogenesis, cell signaling and energy production/storage. Therefore, it is not surprising that ACLY is upregulated in various types of cancer and correlates with poor patient prognosis. However, the role of ACLY in hepatocellular carcinoma (HCC) remains largely unknown. Currently, the net 5 year survival rate of HCC is 19% and its incidence is rapidly increasing in Canada. Unfortunately, Sorafenib and Lenvatinib, the lone first-line standard of treatment drugs for HCC, could only extend median survival by 3 - 4 months. Thus, validation of ACLY as a novel drug target for HCC either alone or in combination with these drugs is of critical interest for improving the standard of care for HCC. The proposed study aims to discover and validate the role of ACLY in HCC through both pharmacological and genetic inhibition of ACLY activity.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wu, Jianhan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~